Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00007
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
BP9a
|
|||||
| Structure |
|
|||||
| Sequence |
CAHLHNRS
|
|||||
| Peptide Type |
Linear
|
|||||
| Receptor Name |
Transferrin receptor protein 1 (TFRC)
|
Receptor Info | ||||
| PDC Transmembrane Types | Cell-penetrating peptides (CPPs) | |||||
| Formula |
C37H60N16O11S
|
|||||
| Isosmiles |
[H]NC(=O)C[C@H](NC(=O)[C@H](Cc1cn([H])cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1cn([H])cn1)NC(=O)[C@H](C)NC(=O)[C@H](CS[H])N[H])C(=O)N[C@@H](CCC/N=C(/N)N[H])C(=O)N[C@@H](CO[H])C(=O)O
|
|||||
| InChI |
InChI=1S/C37H60N16O11S/c1-17(2)7-23(50-33(60)24(8-19-11-42-15-45-19)49-29(56)18(3)47-30(57)21(38)14-65)32(59)51-25(9-20-12-43-16-46-20)34(61)52-26(10-28(39)55)35(62)48-22(5-4-6-44-37(40)41)31(58)53-27(13-54)36(63)64/h11-12,15-18,21-27,54,65H,4-10,13-14,38H2,1-3H3,(H2,39,55)(H,42,45)(H,43,46)(H,47,57)(H,48,62)(H,49,56)(H,50,60)(H,51,59)(H,52,61)(H,53,58)(H,63,64)(H4,40,41,44)/t18-,21-,22-,23-,24-,25-,26-,27-/m0/s1
|
|||||
| InChIKey |
HGMLHCGTVWNMRN-CGGNIPPMSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
937.055
|
Polar area
|
452.1
|
||
|
Complexity
|
936.4348177
|
xlogp Value
|
-6.3594
|
|||
|
Heavy Count
|
65
|
Rot Bonds
|
32
|
|||
|
Hbond acc
|
15
|
Hbond Donor
|
16
|
|||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
BP9a-SS-DOX [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Tumor | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
6.21 ± 1.12 µM
|
|||
| Evaluation Method | CCK-8 assay | ||||
| Description |
The BP9a-SS-DOX conjugate exhibited impressed antiproliferative activity against HepG2 cells with an IC50 value of 6.21 ± 1.12 uM which was lower than that of free DOX.
|
||||
| In Vitro Model | Hepatoblastoma | Hep-G2 cell | CVCL_0027 | ||
BP9a-DOX [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [2] | ||||
| Indication | Tumor | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
18.5 ± 3.77 µM
|
|||
| Evaluation Method | CCK-8 assay | ||||
| Description |
Its antiproliferative activity against HepG2 cells (IC50 18.5 ± 3.77 uM) was lower than that of free DOX.
|
||||
| In Vitro Model | Hepatoblastoma | Hep-G2 cell | CVCL_0027 | ||
References